AZD-3839 is primarily researched for its potential application in the treatment of Alzheimer's disease. It functions as a beta-secretase (BACE1) inhibitor, targeting the enzyme responsible for the production of amyloid-beta peptides. These peptides are key components of amyloid plaques, which are characteristic of Alzheimer's pathology. By inhibiting BACE1, AZD-3839 aims to reduce the formation of amyloid plaques, potentially slowing disease progression. Clinical studies have focused on evaluating its efficacy, safety, and tolerability in patients with mild to moderate Alzheimer's, making it a promising candidate in the development of disease-modifying therapies.